1. In Vivo
  2. >>Archive

DeRoyal Splits in Two

DeRoyal Industries Inc. is spinning off a separate company, iPath Inc., to provide OR infomration systems to hospitals.

As hospitals begin to turn to suppliers for a wider array of value-added services, most product companies, and particularly those in low-tech, high-volume commodity lines, find themselves pressured to oblige. For most companies, those services are offered in the name of selling more products. But now one company, orthopedic soft goods supplier DeRoyal Industries Inc. , has recognized the inherent value of its service offering by spinning off a separate company, iPath Inc., to provide OR information systems to hospitals.

DeRoyal has been in the OR information business since 1983, offering traditional OR information systems like scheduling, surgeon preference cards,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

Sponsored by:

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

How Annexon Reclaimed Its Geographic Atrophy Program After Phase II Miss

The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.

Deals Shaping The Industry, August 2025

An interactive look at pharma, medtech and diagnostics deals made during August 2025. Data courtesy of Biomedtracker.

Rising Leaders 2025: Noam Solomon’s Quest To Create A ‘Google Maps’ Of the Immune System

 
• By David Wild

The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.